Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
US9034837B2 · kind B2 · utility
3Cited by
11References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 26, 2010 |
| Grant date | May 19, 2015 |
| Priority date | — |
| Expiry date | Aug 10, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/3533
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 oligonucleotide, and are made for administration to a primate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.